Vimarsana
Biggest News Aggregation in the World

Page 20 - Robert Blum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Blum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Blum Today - Breaking & Trending Today

SenesTech to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Vimarsana News

SenesTech to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

/PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its second quarter 2023, ended June 30, 2023, after the market close on...

LiqTech International to Discuss Second Quarter 2023 Results on Thursday, August 10, 2023 - Vimarsana News

LiqTech International to Discuss Second Quarter 2023 Results on Thursday, August 10, 2023

/PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company that manufactures and markets highly specialized filtration products and...

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors - Vimarsana News

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

/PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage...

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules - Vimarsana News

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

/PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel...

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules - Vimarsana News

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

PONTE VEDRA, Fla., July 14, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant for certain...